Kintor Pharmaceutical KNTPF Stock
Kintor Pharmaceutical Price Chart
Kintor Pharmaceutical KNTPF Financial and Trading Overview
Kintor Pharmaceutical stock price | 0.21 USD |
Previous Close | 0.61 USD |
Open | 0.61 USD |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 0.61 - 0.61 USD |
52 Week Range | 0.57 - 3.95 USD |
Volume | 1.41K USD |
Avg. Volume | 494 USD |
Market Cap | 274M USD |
Beta (5Y Monthly) | -0.036717 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.29 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
KNTPF Valuation Measures
Enterprise Value | -316565984 USD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 0.18326847 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | 0.331 |
Trading Information
Kintor Pharmaceutical Stock Price History
Beta (5Y Monthly) | -0.036717 |
52-Week Change | -80.80% |
S&P500 52-Week Change | 20.43% |
52 Week High | 3.95 USD |
52 Week Low | 0.57 USD |
50-Day Moving Average | 0.7 USD |
200-Day Moving Average | 1.54 USD |
KNTPF Share Statistics
Avg. Volume (3 month) | 494 USD |
Avg. Daily Volume (10-Days) | 0 USD |
Shares Outstanding | 447.5M |
Float | 311.76M |
Short Ratio | N/A |
% Held by Insiders | 31.26% |
% Held by Institutions | 9.06% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -29.38% |
Return on Equity (ttm) | -60.58% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | -956446016 USD |
Net Income Avi to Common (ttm) | -954369024 USD |
Diluted EPS (ttm) | -0.35 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 876.96M USD |
Total Cash Per Share (mrq) | 1.96 USD |
Total Debt (mrq) | 286.39M USD |
Total Debt/Equity (mrq) | 19.15 USD |
Current Ratio (mrq) | 4.74 |
Book Value Per Share (mrq) | 3.341 |
Cash Flow Statement
Operating Cash Flow (ttm) | -961260032 USD |
Levered Free Cash Flow (ttm) | -681669376 USD |
Profile of Kintor Pharmaceutical
Country | United States |
State | N/A |
City | Suzhou |
Address | No. 20 Songbei Road |
ZIP | 215123 |
Phone | 86 51 2626 39909 |
Website | https://www.kintor.com.cn |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 301 |
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in developing and commercializing a pipeline of small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs in the People's Republic of China and internationally. The company's products pipeline include Proxalutamide, a second generation androgen receptor (AR) antagonist for the treatment of metastatic castration-resistant prostate cancer, AR positive breast cancer, and COVID-19; and Pyrilutamide, an AR antagonist for the androgenetic alopecia (AGA) and acne vulgaris treatment. Its products pipeline comprises ALK-1 antibody for the treatment of metastatic hepatocellular carcinoma (HCC) and various solid tumours; GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris; and PD-L1/TGF-ß, a dual target antibody to treat non-small cell lung cancer, biliary tract cancer, triple negative breast cancer, and HPV-associated tumours. In addition, the company's products pipeline include Detorsertib for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and HCC; and Hedgehog/SMO Inhibitor, an inhibitor of the hedgehog signal transduction pathway to treat blood cancer. Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People's Republic of China.
Q&A For Kintor Pharmaceutical Stock
What is a current KNTPF stock price?
Kintor Pharmaceutical KNTPF stock price today per share is 0.21 USD.
How to purchase Kintor Pharmaceutical stock?
You can buy KNTPF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Kintor Pharmaceutical?
The stock symbol or ticker of Kintor Pharmaceutical is KNTPF.
Which industry does the Kintor Pharmaceutical company belong to?
The Kintor Pharmaceutical industry is Biotechnology.
How many shares does Kintor Pharmaceutical have in circulation?
The max supply of Kintor Pharmaceutical shares is 431M.
What is Kintor Pharmaceutical Price to Earnings Ratio (PE Ratio)?
Kintor Pharmaceutical PE Ratio is now.
What was Kintor Pharmaceutical earnings per share over the trailing 12 months (TTM)?
Kintor Pharmaceutical EPS is -0.29 USD over the trailing 12 months.
Which sector does the Kintor Pharmaceutical company belong to?
The Kintor Pharmaceutical sector is Healthcare.